Sequent Scientific Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sequent Scientific.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	18.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

Jan 05

What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Dec 24

Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?

Dec 12

Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly

Nov 22

Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)

Nov 10

The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It

Oct 20

How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?

Oct 05

Is Sequent Scientific Limited's (NSE:SEQUENT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Sep 04

Do Sequent Scientific's (NSE:SEQUENT) Earnings Warrant Your Attention?

Aug 20

Sequent Scientific Limited's (NSE:SEQUENT) Earnings Haven't Escaped The Attention Of Investors

Jul 30

Does Sequent Scientific (NSE:SEQUENT) Have A Healthy Balance Sheet?

Jul 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sequent Scientific has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:SEQUENT - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	13,705	-1,285	N/A	N/A	N/A
9/30/2023	14,212	-1,457	286	984	N/A
6/30/2023	14,128	-1,410	N/A	N/A	N/A
3/31/2023	14,209	-1,212	-694	168	N/A
12/31/2022	14,380	-186	N/A	N/A	N/A
9/30/2022	14,207	74	-854	-282	N/A
6/30/2022	14,336	263	N/A	N/A	N/A
3/31/2022	14,128	410	-19	306	N/A
12/31/2021	13,909	529	N/A	N/A	N/A
9/30/2021	13,879	713	-98	417	N/A
6/30/2021	13,869	805	N/A	N/A	N/A
3/31/2021	13,616	954	619	1,148	N/A
12/31/2020	13,153	963	N/A	N/A	N/A
9/30/2020	12,735	793	1,327	1,718	N/A
6/30/2020	12,115	794	N/A	N/A	N/A
3/31/2020	11,792	699	746	1,153	N/A
12/31/2019	11,606	702	N/A	N/A	N/A
9/30/2019	11,147	629	408	726	N/A
6/30/2019	10,822	568	N/A	N/A	N/A
3/31/2019	10,393	487	906	1,160	N/A
12/31/2018	9,902	348	N/A	N/A	N/A
9/30/2018	9,446	160	N/A	N/A	N/A
6/30/2018	8,904	36	N/A	N/A	N/A
3/31/2018	8,478	9	-18	452	N/A
12/31/2017	10,457	204	N/A	N/A	N/A
9/30/2017	10,302	352	N/A	N/A	N/A
6/30/2017	9,914	184	N/A	N/A	N/A
3/31/2017	6,836	-113	N/A	-72	N/A
12/31/2016	8,797	-349	N/A	N/A	N/A
9/30/2016	7,592	-430	N/A	N/A	N/A
6/30/2016	6,652	-325	N/A	N/A	N/A
3/31/2016	6,062	-200	N/A	-1	N/A
12/31/2015	5,718	-848	N/A	N/A	N/A
9/30/2015	5,297	-848	N/A	N/A	N/A
6/30/2015	4,789	-535	N/A	N/A	N/A
3/31/2015	4,432	-657	N/A	-235	N/A
12/31/2014	3,779	-676	N/A	N/A	N/A
9/30/2014	3,805	-714	N/A	N/A	N/A
6/30/2014	4,467	-1,125	N/A	N/A	N/A
3/31/2014	3,950	-1,103	N/A	-448	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SEQUENT's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if SEQUENT's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if SEQUENT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SEQUENT's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if SEQUENT's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SEQUENT's Return on Equity is forecast to be high in 3 years time

Sequent Scientific Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to ₹149

Price target decreased to ₹170

Price target decreased to ₹197

Recent updates

Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)

Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024

Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023)

Sequent Scientific Limited Announces Executive Changes

Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024

Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024

Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023

Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer

Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023

Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023

Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra

Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022)

Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet

Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022)

Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director

Price target decreased to ₹149

High number of new and inexperienced directors

Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022)

Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion.

Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022

Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022

First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022)

Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022

Investor sentiment improved over the past week

Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer

Investor sentiment deteriorated over the past week

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022

Price target decreased to ₹170

High number of new and inexperienced directors

Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022

Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO

Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director

CEO, MD & Executive Director recently sold ₹73m worth of stock

Investor sentiment improved over the past week

CEO, MD & Executive Director recently sold ₹84m worth of stock

CEO, MD & Executive Director recently sold ₹23m worth of stock

CEO, MD & Executive Director recently sold ₹27m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to ₹197

Insider recently sold ₹5.7m worth of stock

Investor sentiment deteriorated over the past week

Insider recently bought ₹1.4m worth of stock

Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021)

Investor sentiment deteriorated over the past week

Insider recently sold ₹17m worth of stock

Insider recently sold ₹17m worth of stock

Full year 2021 earnings released: EPS ₹3.87 (vs ₹2.87 in FY 2020)

Insider recently sold ₹1.3m worth of stock

Third quarter 2021 earnings released: EPS ₹1.54 (vs ₹0.83 in 3Q 2020)

New 90-day high: ₹232

Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?

Sequent Scientific Limited to Report Q3, 2021 Results on Feb 03, 2021

New 90-day high: ₹215

Investor sentiment improved over the past week

How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

New 90-day high: ₹181

What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Chief Financial Officer recently sold ₹7.7m worth of stock

Sequent Scientific Limited Appoints Fabian Kausche as an Additional (Non-Executive Non-Independent) Director

Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?

Insider recently sold ₹8.7m worth of stock

New 90-day high: ₹169

Sequent Scientific Limited Announces Launch of Inhouse Developed Halofusol® in EU

Insider recently sold ₹79m worth of stock

Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly

Insider recently sold ₹3.8m worth of stock

Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)

Second quarter 2021 earnings released: EPS ₹0.86

Sequent Scientific Limited Appoints Gregory John Andrews as an Additional Director with Effect from November 6, 2020